It appears that pg 3 is a continuation of "Directions" regarding voting power...
nothing to do with shorting...
HAHA....how do you go from "Strong Buy" to Hold in just a couple days with this
company at this point. Obviously people listen to their babble
Phase III SYNERGY trial: Docetaxel +/- custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis (Poster, Abstract #5009)•Poster: Saturday, May 30, 1:15 PM CDT – S Hall A
•Poster Discussion: Saturday, May 30, 4:45 PM CDT - E Arie Crown Theater
•First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial (Oral Session, Abstract #4503)•Monday, June 1, 9:45 AM CDT - E Arie Crown Theater
•The Borealis-2™ clinical trial: A randomized phase 2 study of OGX-427 (Apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer (Poster, Abstract #TPS4577)•Monday June 1, 1:15 PM CDT – S Hall A, Board #247b
•Addition of apatorsen, an inhibitor of Hsp27, to first-line gemcitabine/carboplatin in advanced squamous cell lung cancer: Design of the Cedar™ study (Poster, Abstract #TPS8111)•Monday June 1, 8:00 AM CDT – S Hall A, Board #431b
Look who the study is designed for...and they didn't stop out for safety...it's going to pop nicely!
You are very correct about the offer....